Skip to main content

Table 2 Multivariate analyses of risk of malignant diseases among biologic users in comparison with matched controls

From: The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study

   All TNF-α inhibitor 1 users Adalimumab 2 Etanercept 3 Rituximab
Biologics Event, number 89 89 8 71 0
Total person-years 16650.63 16624.36 2203.45 10363.75 26.27
IR per 1000 (95% CI) 5.35 (4.23, 6.46) 5.35 (4.24, 6.47) 3.63 (1.11, 6.15) 6.85 (5.26, 8.44) -
nbDMARDs4 Event, number 486 485 51 309 1
Total person-years 65587.93 65485.91 8763.78 41209.78 102.02
IR per 1000 (95% CI) 7.41 (6.75, 8.07) 7.41 (6.75, 8.07) 5.82 (4.22, 7.42) 7.50 (6.66, 8.33) 9.80 (0.00, 29.01)
  HR (95% CI) 0.63 (0.49, 0.80) 0.63 (0.50, 0.81) 0.61 (0.28, 1.33) 0.83 (0.62, 1.10) -
  IRR (95% CI) 0.72 (0.58, 0.90) 0.72 (0.58, 0.91) 0.62 (0.30, 1.31) 0.91 (0.71, 1.18) -
P-value 0.0046 0.0049 0.2147 0.4926 -
  1. 1Includes all patients who have used TNF-α inhibitors, with or without disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids, in comparison with matched controls. 2Use of adalimumab alone, with or without DMARDs or corticosteroids, in comparison with matched controls. 3Use of etanercept alone, with or without DMARDs or corticosteroids, in comparison with matched controls. 4Indicates the event number and total observed person-years of matched subjects from THE nonbiologic DMARDS (nbDMARDs) cohort for each of those using different types of TNF-α inhibitors and rituximab. HR, hazard ratio; IR, incidence rate; IRR, incidence rate ratio.